We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BD's (BDX) Digital Marketplace Set to Improve User Experience
Read MoreHide Full Article
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced the commercial release of a new bdbiosciences.com web and eCommerce site. The digital marketplace has been designed with the aim of providing an improved online purchasing experience for users and their procurement teams.
For investors’ note, the new BD Biosciences website offers a full range of BD’s research, clinical and single-cell multiomic products. This, in turn, makes the online destination a comprehensive marketplace for flow cytometry users.
The newly launched website is available for users in the United States, Canada, Europe, Australia and New Zealand, and is set to be introduced in additional countries later this summer.
The latest release is expected to significantly strengthen BD’s position in the global Biosciences space. The Biosciences business is a part of the broader BD Life Sciences arm of the company.
Significance of the Release
Per management, the reimagined digital marketplace is aimed at empowering its customers with tools and relevant scientific content to make the process of online product search and purchase quicker, easier and more suitable throughout the complete flow cytometry continuum.
The entirely refurbished online purchasing experience brings intuitive navigation, a fully integrated shopping experience and a user interface theme that is expected to address flow cytometry users' buying needs. Tailored dashboards and quick checkout with minimal clicks, all with 24/7 order tracking and support tools are available for reagent purchases.
The eCommerce capability aids in seamless integration with procurement buying systems, thereby enabling customers to view institutional pricing and get internal approvals before placing orders.
Industry Prospects
Per a report by MarketsandMarkets, the global flow cytometry market is projected to grow from an estimated $4.0 billion in 2019 to $6.4 billion by 2025 at a CAGR of 8.3%. Factors like technological advancements in flow cytometers and the growing adoption of its techniques in research activities and clinical trials are likely to drive the market.
Given the market potential, the commercial release of the overhauled digital marketplace is expected to significantly strengthen BD’s business worldwide.
Notable Developments
Of late, BD has witnessed a few notable developments across its businesses.
The company, in June, received the FDA’s 510(k) clearance for its PeritX Peritoneal Catheter System. The system is to be used for the drainage of symptomatic, recurrent non-malignant ascites.
The same month, BD announced that it has been authorized as a Common Vulnerability and Exposures (“CVE”) Numbering Authority via the CVE Program. BD is the first medical technology company with such an authorization.
In May, the company announced the U.S. launch of a Urine Culture Application for use with the BD Kiestra lab automation incubation and imaging system.
Price Performance
Shares of BD have lost 2.9% in the past year compared with the industry’s 28.8% growth and the S&P 500's 40% rise.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, BD carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Veeva Systems Inc. (VEEV - Free Report) , AMN Healthcare Services Inc (AMN - Free Report) and National Vision Holdings, Inc. (EYE - Free Report) .
Image: Shutterstock
BD's (BDX) Digital Marketplace Set to Improve User Experience
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced the commercial release of a new bdbiosciences.com web and eCommerce site. The digital marketplace has been designed with the aim of providing an improved online purchasing experience for users and their procurement teams.
For investors’ note, the new BD Biosciences website offers a full range of BD’s research, clinical and single-cell multiomic products. This, in turn, makes the online destination a comprehensive marketplace for flow cytometry users.
The newly launched website is available for users in the United States, Canada, Europe, Australia and New Zealand, and is set to be introduced in additional countries later this summer.
The latest release is expected to significantly strengthen BD’s position in the global Biosciences space. The Biosciences business is a part of the broader BD Life Sciences arm of the company.
Significance of the Release
Per management, the reimagined digital marketplace is aimed at empowering its customers with tools and relevant scientific content to make the process of online product search and purchase quicker, easier and more suitable throughout the complete flow cytometry continuum.
The entirely refurbished online purchasing experience brings intuitive navigation, a fully integrated shopping experience and a user interface theme that is expected to address flow cytometry users' buying needs. Tailored dashboards and quick checkout with minimal clicks, all with 24/7 order tracking and support tools are available for reagent purchases.
The eCommerce capability aids in seamless integration with procurement buying systems, thereby enabling customers to view institutional pricing and get internal approvals before placing orders.
Industry Prospects
Per a report by MarketsandMarkets, the global flow cytometry market is projected to grow from an estimated $4.0 billion in 2019 to $6.4 billion by 2025 at a CAGR of 8.3%. Factors like technological advancements in flow cytometers and the growing adoption of its techniques in research activities and clinical trials are likely to drive the market.
Given the market potential, the commercial release of the overhauled digital marketplace is expected to significantly strengthen BD’s business worldwide.
Notable Developments
Of late, BD has witnessed a few notable developments across its businesses.
The company, in June, received the FDA’s 510(k) clearance for its PeritX Peritoneal Catheter System. The system is to be used for the drainage of symptomatic, recurrent non-malignant ascites.
The same month, BD announced that it has been authorized as a Common Vulnerability and Exposures (“CVE”) Numbering Authority via the CVE Program. BD is the first medical technology company with such an authorization.
In May, the company announced the U.S. launch of a Urine Culture Application for use with the BD Kiestra lab automation incubation and imaging system.
Price Performance
Shares of BD have lost 2.9% in the past year compared with the industry’s 28.8% growth and the S&P 500's 40% rise.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, BD carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Veeva Systems Inc. (VEEV - Free Report) , AMN Healthcare Services Inc (AMN - Free Report) and National Vision Holdings, Inc. (EYE - Free Report) .
Veeva Systems’ long-term earnings growth rate is estimated at 15.8%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AMN Healthcare’s long-term earnings growth rate is estimated at 6.5%. It currently flaunts a Zacks Rank #1.
National Vision’s long-term earnings growth rate is estimated at 23%. It currently sports a Zacks Rank #1.